Trial Profile
Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bendamustine; Cyclophosphamide; Cytarabine; Etoposide; Melphalan
- Indications Hodgkin's disease; Lymphoma; Sezary syndrome; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms BAL
- 03 Oct 2022 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 03 Oct 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.
- 29 Jul 2021 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.